Evaluating the Safety and Immunogenicity of AGS-v PLUS, a Universal Mosquito-Borne Disease and Mosquito Control Vaccine

Phase 1

Completed

• Conditions: Mosquito-Borne Infectious Diseases
• Interventions: Biological: AGS-v PLUS Vaccine; Biological: Montanide ISA-51 Adjuvant; Biological: Alhydrogel® Adjuvant; Biological: Saline Placebo

• Registration Number: NCT04009824
• Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Brief Summary

The purpose of this study is to evaluate the safety and immunogenicity of AGS-v PLUS, a universal mosquito-borne disease and mosquito control vaccine, in healthy volunteers.

Detailed Description

This study will evaluate the safety and immunogenicity of AGS-v PLUS, a universal mosquito-borne disease and mosquito control vaccine, in healthy volunteers.

Participants will be randomly assigned to five groups.

Participants in Group 1 will receive placebo on Days 1 and 22.

Participants in Group 2 will receive unadjuvanted AGS-v PLUS vaccine on Days 1 and 22.

Participants in Group 3 will receive Montanide ISA-51 adjuvanted AGS-v PLUS vaccine on Day 1 and placebo on Day 22.

Participants in Group 4 will receive Montanide ISA-51 adjuvanted AGS-v PLUS vaccine on Days 1 and 22.

Participants in Group 5 will receive Alhydrogel® adjuvanted AGS-v PLUS vaccine on Days 1 and 22.

Participants will be in the study for approximately 12 months. During this time, they will attend several study visits, which may include physical examinations, blood collection, skin biopsies, and a mosquito feeding procedure. Study staff will also follow up with participants by phone several times throughout the study.

Study Timeline

• Study First Submitted: 2019-07-01
• Study First Submitted QC: 2019-07-03
• Study First Posted: 2019-07-05
• Study Start: 2019-07-08
• Primary Completion: 2020-03-03
• Study Completion: 2021-02-23
• Status Verified: 2022-03
• Results First Submitted: 2022-03-22
• Results First Submitted QC: 2022-04-25
• Last Update Submitted: 2022-04-25
• Results First Posted: 2022-04-28
• Last Update Posted: 2022-04-28

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 51

Inclusion Criteria

• Healthy women and men who are greater than or equal to 18 and less than or equal to 50 years of age.

• Willingness to complete all study visits and comply with all study requirements.

• A male participant is eligible for the study if he agrees to practicing abstinence or using a condom with spermicide plus an acceptable form of contraception (see inclusion criteria below) being used by any female partner from 4 weeks before study start to 12 weeks after the second vaccine administration.

• A female participant is eligible for this study if she is not pregnant or breast feeding and 1 of the following:

  • Of non-child bearing potential (i.e., women who have had a hysterectomy or tubal ligation, or are postmenopausal, as defined by no menses in greater than or equal to 1 year).
  • Of childbearing potential but agrees to practice effective contraception or abstinence for 4 weeks before study initiation and 12 weeks after the second vaccine administration. Acceptable methods of contraception include a female partner who is the sole sexual partner of the female participant, a male partner who is sterile and is the sole sexual partner of the female participant, or a male partner who uses a condom with spermicide plus 1 or more of the following: 1) implants of levonorgestrel; 2) injectable progestogen; 3) an intrauterine device with a documented failure rate of less than 1%; 4) oral contraceptives; and 5) double barrier method including diaphragm.

• Willing to have samples stored for future research.

• Agrees to abstain from alcohol intake for 24 hours before each study visit.

• Agrees to not donate blood or blood products throughout the study.

• Score greater than or equal to 70% on comprehension quiz at screening

Read More

Exclusion Criteria

• Participant has any underlying or current medical condition, which, in the opinion of the Investigator, would interfere with the participation in the study.
• Individual with body mass index (BMI) less than or equal to 18 and greater than or equal to 40.
• Participants who have a clinically significant (as determined by the PI or designee) baseline Grade 1 or greater toxicity, or any Grade 2 or greater toxicity (regardless of clinical significance) by the toxicity table.
• Receipt of blood or blood products including immunoglobulin within 3 months before enrollment.
• Receipt of any unlicensed drug within 3 months or 5.5 half-lives (whichever is greater) before enrollment.
• Receipt of any unlicensed vaccine within 6 months before enrollment.
• Participated in study NCT03055000 testing safety and immunogenicity of AGS-v.
• Self-reported or known history of alcoholism or drug abuse within 6 months before enrollment.
• Self-reported or known history of psychiatric or psychological issues that require treatment and are deemed by the PI or designee to be a contraindication to protocol participation.
• History of a previous severe allergic reaction with generalized urticaria, angioedema, anaphylaxis or anaphylactoid reaction.
• Any condition or event that, in the judgment of the PI or designee, is a contraindication to protocol participation or impairs the volunteer's ability to give informed consent.
• Known allergy to any vaccine component, including adjuvants.
• History of severe immunization reaction.
• Severe allergic reaction to mosquito bites (anaphylaxis)
• Have taken oral or parenteral (including intra-articular) corticosteroids of any dose within 30 days before study vaccination
• Have taken high-dose inhaled corticosteroids* within 30 days before each study vaccination (* High-dose defined per age as using inhaled high dose per reference chart: https://www.nhlbi.nih.gov/sites/default/files/media/docs/asthma_qrg_0_0.pdf)
• Received or plan to receive a licensed, live vaccine within 30 days before or after the study vaccination
• Received or plan to receive a licensed, inactivated vaccine within 14 days before or after study vaccination
• Serologic evidence of infection with HIV, hepatitis B virus, or hepatitis C virus
• Ongoing chronic skin condition, or acute skin condition at the time of vaccination or mosquito feeding, except for mild eczema.
• History of keloid formation after previous biopsies, lacerations, abrasions, surgeries, or other skin procedures (e.g., cosmetic piercings) that are deemed by the PI or designee to be a contraindication to protocol participation.
• Pregnancy, breastfeeding, or planning to become pregnant up to one month after mosquito feeding.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Group 2: AGS-v PLUS Non-Adjuvanted	AGS-v PLUS Vaccine	Participants received 1012 µg of unadjuvanted AGS-v PLUS vaccine on days 1 and 22 by subcutaneous injection
Group 3: AGS-v PLUS + Adjuvant Montanide ISA-51 + Placebo	AGS-v PLUS Vaccine	Participants received 1012 µg of AGS-v PLUS and Montanide ISA-51 on day 1 and placebo on day 22 by subcutaneous injection
Group 3: AGS-v PLUS + Adjuvant Montanide ISA-51 + Placebo	Saline Placebo	Participants received 1012 µg of AGS-v PLUS and Montanide ISA-51 on day 1 and placebo on day 22 by subcutaneous injection
Group 1: Saline Placebo	Saline Placebo	Participants received placebo on days 1 and 22 by subcutaneous injection
Group 4: AGS-v PLUS + Montanide ISA-51	AGS-v PLUS Vaccine	Participants received 1012 µg of AGS-v PLUS + Montanide ISA-51 on days 1 and 22 by subcutaneous injection
Group 4: AGS-v PLUS + Montanide ISA-51	Montanide ISA-51 Adjuvant	Participants received 1012 µg of AGS-v PLUS + Montanide ISA-51 on days 1 and 22 by subcutaneous injection
Group 5: AGS-v PLUS + Alhydrogel® Adjuvant	AGS-v PLUS Vaccine	Participants received 1012 µg of AGS-v PLUS and Alhydrogel® on days 1 and 22 by subcutaneous injection
Group 5: AGS-v PLUS + Alhydrogel® Adjuvant	Alhydrogel® Adjuvant	Participants received 1012 µg of AGS-v PLUS and Alhydrogel® on days 1 and 22 by subcutaneous injection
Group 3: AGS-v PLUS + Adjuvant Montanide ISA-51 + Placebo	Montanide ISA-51 Adjuvant	Participants received 1012 µg of AGS-v PLUS and Montanide ISA-51 on day 1 and placebo on day 22 by subcutaneous injection

Primary Outcome Measures

Name	Time	Method
Mean log10 Titer in Serum AGS-v PLUS Specific Immunoglobulin Titers	Day 43	Mean log10 titer in serum AGS-v PLUS specific immunoglobulin E (IgE), immunoglobulin G (IgG), and immunoglobulin M (IgM) titers were assessed using enzyme-linked immunosorbent assay (ELISA)
Mean log10 Concentration in Th1 and Th2 Cytokine Responses	Day 43	Mean log10 concentration in Th1 (IFN-gamma) and Th2 (IL-4) cytokine responses after in vitro exposure of peripheral blood mononuclear cells (PBMCs) with AGS-v PLUS antigens assessed using enzyme-linked immunosorbent assay (ELISA)
Mean log10 Fold Change in Serum AGS-v PLUS Specific Immunoglobulin Titer	Day 1 and Day 43	Mean log10 fold change in serum AGS-v PLUS specific immunoglobulin G (IgG), immunoglobulin M (IgM) and immunoglobulin E (IgE) titers from day 1 to day 43 assessed using enzyme-linked immunosorbent assay (ELISA). The fold change from day 1 to day 43 is calculated by dividing the antibody titer for a specific isotype i.e. IgE at day 43 by the titer at day 1. In order to stabilize the variance, the log10 of the fold change was used in the analyses.
Incidence of Severity of Treatment Emergent Adverse Events (AEs) by Grade	1 year	A treatment emergent adverse event is any untoward medical occurrence in a human subject that manifest after administration of the study treatment, whether or not considered related to the treatment. AE severity was graded using FDA Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September 2007 or the following grading scale: Grade 1 (Mild) Events causing no or minimal interference with daily activity and not requiring medical intervention Grade 2 (Moderate) Events causing greater than minimal interference with daily activity but not requiring medical intervention Grade 3 (Severe) Events causing inability to perform daily activity and/or requiring medical intervention Grade 4 (Potentially Life-Threatening)\* Events causing inability to perform basic self-care functions OR medical or operative intervention indicated to prevent permanent impairment, persistent disability, or death Grade 5 (Death) Events causing death
Mean log10 Fold Change in Th1 and Th2 Cytokine Responses	Day 1 and Day 43	Mean log10 fold change in Th1 (IFN-gamma) and Th2 (IL-4) cytokine responses after in vitro exposure of peripheral blood mononuclear cells (PBMCs) with AGS-v PLUS antigens from day 1 to day 43 assessed using enzyme-linked immunosorbent assay (ELISA). The fold change from day 1 to day 43 is calculated by dividing the antigen titer for a specific isotype i.e. IFN-gamma at day 43 by the titer at day 1. In order to stabilize the variance, the log10 of the fold change was used in the analyses.

Secondary Outcome Measures

Name	Time	Method
Mean log10 Concentration in Th1 and Th2 Cytokine Responses	Day 50	Mean log10 concentration in Th1 (IFN-gamma) and Th2 (IL-4) cytokine responses after in vitro exposure of peripheral blood mononuclear cells (PBMCs) with AGS-v PLUS antigens seven days after mosquito feeding assessed using enzyme-linked immunosorbent assay (ELISA)
Mean Number of Eggs Laid Per Mosquito Post Feeding	Day 43	Mean number of eggs laid per Aedes aegypti and Aedes albopictus female mosquito post feeding on study participants
Mean log10 Titer in Serum AGS-v PLUS Specific Immunoglobulin Titer	Day 50	Mean log10 titer in serum AGS-v PLUS specific immunoglobulin G (IgG), immunoglobulin M (IgM) and immunoglobulin E (IgE) titers seven days after mosquito feeding assessed using enzyme-linked immunosorbent assay (ELISA)
Mean log10 Fold Change in Th1 and Th2 Cytokine Responses	Day 43 and Day 50	Mean log10 fold change in Th1 (IFN-gamma) and Th2 (IL-4) cytokine responses after in vitro exposure of peripheral blood mononuclear cells (PBMCs) with AGS-v PLUS antigens seven days after mosquito feeding assessed using enzyme-linked immunosorbent assay (ELISA). The fold change from day 43 to day 50 is calculated by dividing the antigen titer for a specific isotype i.e. IFN-gamma at day 50 by the titer at day 43. In order to stabilize the variance, the log10 of the fold change was used in the analyses.
Mean log10 Fold Change in Serum AGS-v PLUS Specific Immunoglobulin Titer	Day 43 and Day 50	Mean log10 fold change in serum AGS-v PLUS specific immunoglobulin G (IgG), immunoglobulin M (IgM) and immunoglobulin E (IgE) titers seven days after mosquito feeding assessed using enzyme-linked immunosorbent assay (ELISA). The fold change from day 43 to day 50 is calculated by dividing the antibody titer for a specific isotype i.e. IgE at day 50 by the titer at day 43. In order to stabilize the variance, the log10 of the fold change was used in the analyses.
Mean Days of Mosquitoes Survival Post Feeding	Day 43	Mean days of Aedes aegypti and Aedes albopictus female mosquitoes survival post feeding on study participants

Trial Locations

Locations (1)

University of Maryland School of Medicine - Center for Vaccine Development - Baltimore; 🇺🇸 Baltimore, Maryland, United States